Acute Pain Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

October 21 23:32 2021
Acute Pain Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
DelveInsight Business Research LLP
“Acute Pain Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Acute Pain market. A detailed picture of the Acute Pain pipeline landscape is provided, which includes the disease overview and Acute Pain treatment guidelines.

DelveInsight’s “Acute Pain Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Acute Pain pipeline landscapes. It comprises Acute Pain pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Acute Pain therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Acute Pain pipeline products.  

   

Some of the key takeaways of the Acute Pain Pipeline Report

  • Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Dsuvia (Sufentanil), Zynrelef (HTX-011), Zipsor, Ubrogepant, Oliceridine injection (TRV130), etc., are developing therapies for the treatment of Acute Pain.

  • Emerging therapies such as  AcelRx Pharmaceuticals, Heron Therapeutics, Depomed, Allergan, Trevena, are expected to have a significant impact on the  Acute Pain market in the coming years.

Get an overview of pipeline landscape @ Acute Pain Clinical Trials Analysis 

Acute Pain Overview

Acute pain is defined as “an expected physiologic experience of injurious stimuli that can become pathologic, is normally sudden in onset, time-limited, and motivates behaviors to avoid actual or potential tissue injuries.” The presence of pain often means that something is wrong. Each individual is the best judge of his or her own pain. There are different types of pain; basically, they are categorized into two forms, i.e., acute pain and chronic pain. 

Acute Pain Emerging Drugs

  • Dsuvia (Sufentanil): AcelRx Pharmaceuticals

  • Zynrelef (HTX-011): Heron Therapeutics

  • Zipsor: Depomed

  • Ubrogepant: Allergan

  • Oliceridine injection (TRV130): Trevena

For further information, refer to the detailed report @ Acute Pain Pipeline Therapeutics 

Scope of Acute Pain Pipeline Drug Insight    

  • Coverage: Global 

  • Major Players: Dsuvia (Sufentanil), Zynrelef (HTX-011), Zipsor, Ubrogepant, Oliceridine injection (TRV130), and others.

  • Pipeline Therapies: AcelRx Pharmaceuticals, Heron Therapeutics, Depomed, Allergan, Trevena, and others.

Table of Contents

1

Acute Pain Report Introduction

2

Acute Pain Executive Summary

3

Acute Pain Overview

4

Acute Pain- Analytical Perspective In-depth Commercial Assessment

5

Acute Pain Pipeline Therapeutics

6

Acute Pain Late Stage Products (Phase II/III)

7

Acute Pain Mid Stage Products (Phase II)

8

Acute Pain Early Stage Products (Phase I)

9

Acute Pain Preclinical Stage Products

10

Acute Pain Therapeutic Assessment

11

Acute Pain Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Acute Pain Key Companies

14

Acute Pain Key Products

15

Acute Pain Unmet Needs

16 

Acute Pain Market Drivers and Barriers

17

Acute Pain Future Perspectives and Conclusion

18

Acute Pain Analyst Views

19

Appendix

20

About DelveInsight

Get a customized pipeline report @ Acute Pain Drugs Pipeline Report 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/